A：Key achievements highlighted in the speech include CVS Health's progress in simplifying the healthcare experience, making healthcare more affordable and accessible for American families, and the ongoing work to realize CVS Health's ambition of becoming America's most trusted healthcare company. The company has also made strides in strengthening operations and improving financial performance.

A：The adjusted operating income of $2.6 billion and adjusted earnings per share of $1.90 reported in the fourth quarter are significant because they indicate strong financial performance. The reaffirmation of full-year 2026 adjusted EPS guidance range and the outperforming adjusted earnings per share and operating cash flow from 2025 also signify CVS Health's financial strength and its potential for continued growth.

A：The pescay Health Plan of the Year award is important for CVS Health as it recognizes the company for high-quality offerings, technological innovation, and best-in-class experiences delivered to members, partners, and providers. The recognition is a validation of the company's disciplined execution and relentless commitment, and it signifies progress in driving distinction and improving simplicity in healthcare.

A：The 2027 Medicare Advantage Advanced Rate Notice is disappointing for CVS Health as the proposed rate does not align with the industry's medical cost trend. CVS Health is advocating for appropriate funding to ensure access and the stability and sustainability of the Medicare Advantage program, which is relied on by more than half of the seniors in the country. The company remains focused on margin recovery and has multiple capabilities aimed at serving Medicare Advantage members.

A：CVS Health faces challenges with the proposed rate for the Medicare Advantage program not matching industry medical cost trends. Despite this, the company is committed to recovering margins in the Medicare business and continues to focus on ensuring sustainable and compelling product offerings. Additionally, CVS Health supports CMS's efforts to align diagnosis to encounters with medical professionals and recognizes the benefits of value-based care.

A：Signify contributes to CVS Health's strategy by providing increased access to health evaluation services, particularly in rural areas or for members with barriers to office-based care. Signify plays a critical role in facilitating connections back into the healthcare system to close gaps in care and helps Aetna and other health plan partners understand the holistic health of their members, which is vital to ensuring appropriate care and maintaining the company's focus on innovation to meet seniors' needs.

A：CVS Health is aligned with CMS and recognizes the benefits of value-based care in delivering significant savings, better engagement, and outcomes. The company supports legislation that does not impact the ability to create competition in the supply chain and that increases transparency for all stakeholders. CVS Health believes in the importance of value-based care and sees it as a way to ensure patients receive the right medicine at the lowest cost while delivering superior experiences.

A：CVS Health is expanding its services by thoughtfully increasing the number of patients served by Oak Street Health, which focuses on providing services to seniors. The company is taking steps to create a more sustainable and attractive business over the long term and will continue making leading models like Oak Street available to more seniors.

A：CVS Health's pharmacy businesses have made significant progress, with the value proposition of Caremark and its pharmacy services becoming more important. The company is combating the impact of branded drug manufacturers increasing prices by driving savings and delivering the lowest net cost to clients and their members. CVS Health is adapting to market dynamics and regulatory changes, supporting legislation that fosters competition and transparency, and maintaining durable margins while ensuring prescription affordability.

A：CVS Health supports legislation that does not impact the company's ability to create competition in the supply chain and that enhances transparency for all stakeholders, including enabling savings at the pharmacy counter. The company supports changes that align with its direction and the core principles of its True Cost model, as it hopes this legislation will lead to greater adoption of the model and improve market transparency.

A：CVS Pharmacy has exceeded expectations in 2025, establishing a new trajectory of at least plant earnings annually starting in 2026. This turnaround is attributed to investments in colleagues, technology, and the consumer experience, which transformed consumer engagement at a national scale and maintained the company's position as a trusted provider in local communities. CVS Pharmacy's ability to transition to a cost-based reimbursement model has created a more transparent and stable market for the long term.

A：Aetna generates savings for its members and clients through various means including network negotiations that resulted in over $235 billion in savings, commerce negotiations with drug manufacturers that deliver an additional $45 billion in annual savings, and care management programs, local pharmacists, and value-based care providers using clinical interventions to keep members and patients healthy and avoid costly conditions.

A：Aetna counters inflationary pressures by working to make healthcare systems easier to navigate and reduce administrative obstacles. They streamline processes like prior authorizations, which have the fewest medical services subject to such authorizations, and ensure that 95% of eligible authorizations are approved within 24 hours. Additionally, Aetna simplifies and expedites the authorization process for certain conditions and procedures to improve care, reduce frustration, and enhance health outcomes.

A：Aetna has made the prior authorization process simpler by reducing the number of authorizations required, such as through condition-specific bundled authorizations that replace multiple approvals with one. They have also expedited the process, with 95% of eligible authorizations approved within 24 hours and many completed instantaneously. Furthermore, they have simplified and expedited authorizations for certain conditions and procedures like IVF.

A：Aetna's consumer engagement and technology have been instrumental in managing medical costs by streamlining processes and enhancing the efficiency of healthcare delivery. They have used these tools to improve outcomes and experiences at lower costs for consumers and patients, and they expect this approach to remain effective in the future.

A：Aetna delivered strong financial performance with a full year revenue of over $400 billion, adjusted EPS of $6.75, and operating cash flow of $10.6 billion. For the fourth quarter, Aetna had revenue of over $105 billion, adjusted operating income of about $2.6 billion, and adjusted EPS of $1.90. However, these results were modestly down from the prior year due to expected changes in the seasonality of the Medicare Part D program.

A：Aetna's outlook for 2026 includes a revenue guidance of at least $400 billion and an expectation for full-year 2026 adjusted EPS in a range of $7.00 to $7.20. The company is encouraged by its recent performance and aims to continue delivering on its financial commitments while striving to outperform through thoughtful targets and strategic execution.

A：The updated outlook for full year cash flow from operations is at least $5 billion dollars, reflecting the impact from certain payments that shifted from 2026 into late 2025 and the persistence of underlying outperformance.

A：The rate notice is more impactful to the Aetna business, which remains an important part of CVS Health's strategy, but is a much smaller portion of the overall business. The impact of the rate notice on Aetna business is significant, but the exact details were not provided in the transcript.

A：CVS Health is committed to Medicare recovery and expects to continue making meaningful progress in 2026, similar to the progress made in 2025. The company sees the Medicare Advantage program as an important offering for lowering costs and improving care for beneficiaries. They are confident in their ability to drive the business forward and maintain the strong foundation laid for the Medicare business.

A：CVS Health does not believe the proposed rates are sufficient to cover the current medical costs and is advocating for better alignment with the trends in medical cost. Despite the disappointment in the preliminary rates for 2027, the company's commitment to achieving Aetna margins remains unchanged and is not expected to impact their long-standing enterprise guidance provided in December during the investor day.

A：The strategy for the Medicare business is to build on the momentum from 2026 and continue driving the business back to target margins in 2027. The company plans to maintain its strong foundation, improve the geographic and product mix, and continue to execute successfully on bids and the Annual Enrollment Period (AEP). They expect modest contractions and the business is returning to target margins as part of their recovery strategy.

A：CVS Health is supportive of regulation that doesn't impede the ability to create competition in the supply chain. Regarding the FTC's proposal, it is unclear whether it would hinder the company's ability to negotiate in the supply chain or affect ongoing CBS Health settlement discussions. CVS Health's position is to ensure that any regulation allows for continued competition and lowers prices on the pharmaceutical supply chain.

A：There is clarity on where reform is coming from in the PBM industry, and the good news is that there's an understanding of how to operate and run the business in light of the anticipated changes, giving time to implement necessary adjustments.

A：The industry has been responding to the need for market change with tools and strategies like true cost on the PBM side and cost management at retail, which has been anticipated and led by the speaker's company.

A：True cost has been built with transparency, durability, and stable margins, which is aligned with the industry's dynamic nature. It is believed that the margin profile will remain similar and underlying growth for Caremark will continue despite the evolution of profit pools.

A：PCW is seen as a foundation for the future, having delivered another strong quarter with results driven by high levels of service and colleague engagement. The company aims to continue gaining share with a focus on operational efficiencies, technology, and AI. The competitive position is expected to be maintained and advanced, driven by factors such as cost-based reimbursement, front store performance, and investments in colleagues and technology.

A：The positive performance of the front store in 2025 was driven by initiatives focused on delivering value and driving loyalty through improved value propositions, localizing the assortment to meet customer needs, providing excellent customer service, and investing in colleagues, technology, and AI.

A：The company's strategy for 2026 includes expanding the role it plays in customers' health and retail convenience, script growth driven by innovation, adherence, and strong service levels, and continued investment in technology and AI to improve consumer experience.

A：The company serves about 18 million members, which is the highest membership level in the last decade. The commercial business performance is strong, driven by better-than-expected retention and innovative approaches. Although fully insured business pricing remains under pressure, growth in the self-funded business has been a positive influence. The company is confident in its ability to continue advancing the commercial business.

A：The Medicaid business has performed in line with expectations, with a strong year of acquisitions in 2025. The company plans to continue focusing and disciplining efforts in the Medicaid business, being cautious and prudent, and working closely with state partners to ensure adequate rates while maintaining clinical and operational excellence.

A：MLR expectations for 2026 may vary depending on the performance of various business segments such as MA, Medicaid, and commercial. Better performance in MA and Medicaid may result in improved MLR, whereas adverse performance in these areas could lead to a worse MLR. Factors such as retention rates, product innovations, and approach with sophisticated purchasers of healthcare will impact the MLR expectations.

A：The expectations for 2026 include another year of margin improvement across the businesses, driven by a rational and disciplined approach to pricing in individual and PDP products in Medicare, repricing in the group MA business from a Medicaid perspective, and maintaining pricing discipline in the commercial segment. A strong focus on the fundamentals and a culture that aligns more than 50,000 colleagues towards returning the business to target margins and leading capability in consumer solutions is anticipated to contribute to this improvement.

A：The specific investments for 2026 mentioned include the utilization of artificial intelligence (AI) to reimagine the healthcare experience and align with the needs of the consumer. This investment aims to ensure each business is best in class, assist with cost and growth goals, and reinvest product innovation, with a particular focus on the Open Engagement Platform.

A：The Open Engagement Platform is expected to play a critical role in creating the next generation of health care engagement. With over 185 million consumers engaging with the company annually, the platform is positioned to leverage the company's existing capabilities and trusted brand to improve health engagement, the quality of healthcare, and lower the overall total cost of care.

A：The anticipated trends in each sub-segment of the health insurance business include a continued focus on rational, disciplined pricing in individual and B2B products in Medicare, repricing in group MA from a Medicaid perspective, and the potential for stable margins in the Medicaid business. The company is off to a good start, cautious in the high trend environment, and maintains a strong commercial business that performs well amid dynamic economic conditions.